MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5826/dpc.1504a5639

Медицинская библиотека · Dermatology practical & conceptual · 2025

Dupilumab: an Additional Arrow in the Quiver for Prurigo Nodularis? Data From a Real-Life Setting.

Di Caprio Roberta, Caccavale Stefano, Di Brizzi Eugenia Veronica, Giorgio Caterina Mariarosaria, Stefaniak Aleksandra, Argenziano Giuseppe, Balato Anna

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Prurigo nodularis (PN) management remains a significant challenge due to its chronicity, treatment resistance, and scarcity of approved treatments and to its impact on patients' quality of life.

OBJECTIVE

The aim of this study was to assess PN therapeutic management in a real-life setting.

METHODS

In this prospective observational study, 90 patients diagnosed with moderate-to-severe PN were included. Patients were each prescribed therapies available for PN according to symptom severity, consistent with treatment guidelines; only those undergoing systemic therapies were included. Disease severity was evaluated through the measurements of Investigator's Global Assessment (IGA) score, Numeric Rating Scale (NRS) for pruritus, and Dermatology Life Quality Index (DLQI) at the beginning of the study (week 0 - W0 ) and after a 6-month period of treatment (W24).

RESULTS

At W0, patients were prescribed antidepressants (41.0%), dupilumab (34.0%), antihistamines (23.0%), phototherapy (4.0%) or nemolizumab (2.0%). At W24, patients on dupilumab achieved an IGA score of 0 or 1 and a ≥4-point NRS reduction, more than those on antidepressants (44.5% vs 16.7% and 54.4% vs 16.7%, respectively). The average DLQI score was reduced by 14 points in the dupilumab group, compared to a 6-point reduction in the antidepressant group.

CONCLUSIONS

Our findings reflect the real-world practice of treating PN and support the use of dupilumab as a new effective treatment option, with significant improvements in pruritus, quality of life, and disease severity compared to antidepressant therapy, suggesting its potential as a preferred therapeutic option for PN.

Для цитирования: Di Caprio Roberta, Caccavale Stefano, Di Brizzi Eugenia Veronica, Giorgio Caterina Mariarosaria, Stefaniak Aleksandra, Argenziano Giuseppe, Balato Anna. Dupilumab: an Additional Arrow in the Quiver for Prurigo Nodularis? Data From a Real-Life Setting.. Dermatology practical & conceptual. 2025. DOI: 10.5826/dpc.1504a5639.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.